Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Status Completed

Clinical Trial Summary

This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Assess the anti tumor activity and toxicity profile of pazopanib hydrochloride in patients with metastatic urothelial cancer.

SECONDARY OBJECTIVES:

I. Evaluate the pharmacokinetics of pazopanib hydrochloride in these patients. II. Evaluate pre- and post-treatment changes in circulating endothelial cells, monocytes and platelets, and angiogenesis-related factors in these patients.

OUTLINE: This is a multicenter study. Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection periodically for correlative studies and pharmacological studies. Samples are analyzed for vascular endothelial growth factor (VEGF) and soluble VEGF receptor II concentration via ELISA. Circulating endothelial cells are also measured.

After completion of study treatment, patients are followed for 1 year. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Carcinoma, Transitional Cell
Distal Urethral Cancer
Kidney Neoplasms
Proximal Urethral Cancer
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder
Ureteral Neoplasms
Urethral Cancer Associated With Invasive Bladder Cancer
Urethral Neoplasms
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT00471536
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	August 2008
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02122172` - Afatinib in Advanced Refractory Urothelial Cancer	Phase 2
Completed	`NCT03229278` - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	Phase 1
Completed	`NCT01846520` - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers	N/A
Completed	`NCT01938573` - Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer	Phase 1/Phase 2
Terminated	`NCT00112905` - Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium	Phase 2
Completed	`NCT00072150` - Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma	Phase 2
Terminated	`NCT00072137` - Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy	Phase 1
Completed	`NCT00028756` - Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium	Phase 3
Completed	`NCT00407485` - VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium	Phase 2
Terminated	`NCT00003452` - Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder	Phase 2
Completed	`NCT00003167` - Gene Therapy in Treating Patients With Advanced Bladder Cancer	Phase 1
Completed	`NCT00005831` - Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer	Phase 2
Completed	`NCT00021099` - Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer	Phase 2
Terminated	`NCT01382706` - Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder	Phase 2
Active, not recruiting	`NCT04267575` - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites	N/A
Terminated	`NCT01954173` - Adjuvant Radiation for High Risk Bladder Cancer	N/A
Terminated	`NCT00004856` - Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium	Phase 2
Active, not recruiting	`NCT04670445` - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer	N/A
Terminated	`NCT01282333` - Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT01828736` - Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma	Phase 2